InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 820.20K | 1.12M | 1.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 820.20K | 1.12M | 1.30M |
| Cost of Revenue | -- | -- | 636.00K | 717.00K | -- |
| Gross Profit | -- | -- | 184.20K | 403.20K | -- |
| SG&A Expenses | 2.36M | 1.74M | 1.62M | 1.53M | 1.26M |
| Depreciation & Amortization | 48.40K | 51.70K | 53.20K | 53.20K | 52.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.21M | 2.82M | 2.94M | 2.88M | 1.89M |
| Operating Income | -3.21M | -2.82M | -2.12M | -1.76M | -1.89M |
| Income Before Tax | -4.84M | -2.79M | -2.03M | -1.73M | -1.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.84M | -2.79M | -2.03M | -1.73M | -1.83M |
| Earnings from Discontinued Operations | -996.30K | -174.60K | -- | -- | 46.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.84M | -2.97M | -2.03M | -1.73M | -1.79M |
| EBIT | -3.21M | -2.82M | -2.12M | -1.76M | -1.89M |
| EBITDA | -3.16M | -2.77M | -2.07M | -1.71M | -1.84M |
| EPS Basic | -1.09 | -0.73 | -0.51 | -0.44 | -1.20 |
| Normalized Basic EPS | -0.37 | -0.43 | -0.32 | -0.27 | -0.77 |
| EPS Diluted | -1.09 | -0.73 | -0.51 | -0.44 | -1.20 |
| Normalized Diluted EPS | -0.37 | -0.43 | -0.32 | -0.27 | -0.77 |
| Average Basic Shares Outstanding | 5.34M | 4.05M | 3.95M | 3.95M | 1.49M |
| Average Diluted Shares Outstanding | 5.34M | 4.05M | 3.95M | 3.95M | 1.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |